



**EVALUATIONS AND REGISTRATION DIVISION**

**EVRF34**

**APPLICANT'S SCREENING CHECKLIST FOR REGISTRATION OF HUMAN BIOLOGICAL MEDICINES**

International Non-proprietary Name (INN) of the drug substance, strength, pharmaceutical form.	
Proprietary Product or Trade name (if relevant)	
Number of binders	
Samples <i>(At least 2 market packs should have been submitted)</i>	
Fee	

SECTION	DOCUMENTS	Submitted?		
		Yes	No	Location and any relevant comments
<b>Module 1</b>	<b>Administrative and Regional Information</b>			
	<b>Completed, signed and dated MC8 form</b>			
	<b>Package insert</b>			
	<b>Labels</b>			
	<b>Current GMP status of manufacturing sites</b>			
	<b>GMP certification for each drug substance manufacturing site</b>			
	<b>GMP certification for each drug product manufacturing site (if different from drug substance manufacturing site)</b>			
	<b>Risk Management Plan</b>			
<b>Module 2</b>	<b>COMMON TECHNICAL DOCUMENT SUMMARIES</b>			
<b>2.3</b>	<b>Quality Overall Summary (QOS) (In MS WORD format)</b>			
<b>Module 3</b>	<b>QUALITY</b>			

<b>3.2.S</b>	<b>DRUG SUBSTANCE</b>			
<b>3.2.S.1</b>	<b>General information</b>			
<b>3.2.S.1.1</b>	<b>Nomenclature</b>			
<b>3.2.S.1.2</b>	<b>Structure</b> Schematic of amino acid sequence, including indication of any glycosylation sites, etc			
<b>3.2.S.1.3</b>	<b>General properties</b> A discussion rather than presentation of specifications			
<b>3.2.S.2</b>	<b>MANUFACTURE</b>			
<b>3.2.S.2.1</b>	<b>Manufacturer and address</b>			
<b>3.2.S.2.2</b>	<b>Description of manufacturing process and process controls</b> Flow diagram of manufacturing/fermentation process Batch and scale definition			
<b>3.2.S.2.3</b>	<b>Control of Materials</b>			
	<b>Development Genetics</b> <i>Origin of the gene, description of the gene construction, rationale behind the gene construct, genetic stability</i> <i>Refer to ICH Q5B</i>			
	<b>Analysis of expression construct</b> <i>Refer to ICH Q5B</i>			
	<b>Source, history of establishment and identification of producer strain/ cell line</b> <i>Refer to ICH Q5D</i>			
	<b>Cell banking system</b> <i>Refer to ICH Q5D</i>			
	<b>Cell bank characterization and testing</b> <i>Refer to ICH Q5D</i>			
	<b>Control of material of biologic origin (e.g. monoclonal antibody purification columns, blood/plasma derivatives)</b>			
	<b>Viral safety evaluation</b> <i>Refer to ICH Q5A. This data may also be located in section 3.2.S.2.5</i>			

3.2.S.2.4	<b>Control of critical steps and intermediates</b>			
3.2.S.2.5	<b>Process Validation and/or Evaluation</b>			
3.2.S.2.6	<b>Manufacturing Process Development</b> Evolution of the manufacturing process Comparability assessment (non-clinical, clinical, stability lots)			
3.2.S.3	<b>CHARACTERISATION</b>			
3.2.S.3.1	<b>Elucidation of Structure and other Characteristics</b> <ul style="list-style-type: none"> <li>• Primary, secondary and tertiary structure</li> <li>• Physicochemical characterization</li> <li>• Biological characterization, etc</li> </ul>			
3.2.S.3.2	<b>Impurities</b> <ul style="list-style-type: none"> <li>• Cell-derived impurities</li> <li>• Process-derived impurities</li> <li>• Product-related impurities</li> </ul>			
3.2.S.3.2	<b>Impurities</b>			
3.2.S.4	<b>CONTROL OF Drug Substance</b>			
3.2.S.4.1	<b>FPP manufacturer's and Drug Substance manufacturer's Specifications for the Drug substance</b>			
3.2.S.4.2	<b>FPP manufacturer's and Drug Substance manufacturer's Analytical Procedures for Drug Substance</b>			
3.2.S.4.3	<b>FPP manufacturer's and Drug Substance manufacturer's Validation data for Analytical Procedure</b>			
3.2.S.4.4	<b>Batch analysis data</b> <i>Should include the lot(s) used to manufacture the clinical batch(es)</i>			
3.2.S.4.5	<b>Justification of specifications</b>			
3.2.S.5	<b>Reference standards</b> <ul style="list-style-type: none"> <li>• History of reference materials</li> <li>• Preparation of reference materials</li> <li>• Characterisation of reference materials</li> </ul>			
3.2.S.6	<b>Container closure system</b>			
	<b>Specifications</b>			
	<b>Test Methods</b>			
3.2.S.7	<b>Stability</b>			
3.2.S.7.3	<b>Forced degradation studies</b>			
	<b>Accelerated Stability Studies &amp; Real-Time Stability Studies</b> <i>Refer to ICH Q5B</i>			
3.2.S/3.2.R	<b>Comparability Exercise</b>			

	<i>Candidate biosimilar vs Reference product Comparison of structures, physicochemical attributes, biological activity, etc. Must include at least 10 lots of the reference and at least 6 lots of the candidate biosimilar</i>			
<b>3.2.P</b>	<b>FINISHED PHARMACEUTICAL PRODUCT (FPP)</b>			
<b>3.2.P.1</b>	<b>Description and Composition of the FPP</b>			
	<b>Section 77A Undesirable Ingredients present in formulation</b>			
<b>3.2.P.2</b>	<b>Pharmaceutical Development</b>			
<b>3.2.P.2.3</b>	<b>Manufacturing Process Development</b> Filter-product compatibility studies Filter microbial retention studies			
<b>3.2.P.2.5</b>	<b>Microbial Attributes</b> In-use stability data for multi-dose products			
<b>3.2.P.2.6</b>	<b>Compatibility</b> Compatibility of the drug product with reconstitution diluent(s)			
<b>3.2.P.3</b>	<b>Manufacture</b>			
<b>3.2.P.3.1</b>	<b>Manufacturer(s) name(s) and physical address(es)</b>			
<b>3.2.P.3.2</b>	<b>Batch Formula</b>			
<b>3.2.P.3.3</b>	<b>Description of manufacturing process and process controls</b>			
<b>3.2.P.3.4</b>	<b>Control of critical steps and intermediates</b>			
<b>3.2.P.3.5</b>	<b>Process validation</b>			
	Media fill studies			
	Manufacturing process validation			
	Validation of sterilization of vials, rubber bungs, syringes, etc			
<b>3.2.P.4</b>	<b>Control of Excipients</b>			
<b>3.2.P.4.1</b>	<b>Specifications</b>			
<b>3.2.P.4.2</b>	<b>Analytical Procedures</b> Only required if specifications are non-compendial			
<b>3.2.P.4.5</b>	<b>Excipients of Human or Animal Origin</b> BSE / TSE free certification			
<b>3.2.P.4.6</b>	<b>Novel excipients</b>			

	Provide information provided as per full API Section			
<b>3.2.P.5</b>	<b>Control of FPP</b>			
<b>3.2.P.5.1</b>	<b>Specification(s) of Finished Pharmaceutical Product (FPP)</b>			
<b>3.2.P.5.2</b>	<b>Analytical Procedures</b>			
<b>3.2.P.5.3</b>	<b>Validation of Analytical Procedures</b>			
<b>3.2.P.5.4</b>	<b>Batch analyses data for at least two batches</b>			
<b>3.2.P.5.5</b>	<b>Characterisation of Impurities</b>			
<b>3.2.P.6</b>	<b>Reference Standards</b>			
<b>3.2.P.7</b>	<b>Container- Closure System</b>			
	<b>Test Methods</b>			
	<b>Specifications</b>			
<b>3.2.P.8</b>	<b>Stability</b>			
<b>3.2.P.8.3</b>	<b>Photostability Data</b>			
	<b>Accelerated stability data</b> <i>e.g., 25°C/60%RH</i>			
	<b>Long-term stability data</b> <i>e.g., 5±3°C</i>			
<b>3.2.R</b>	<b>REGIONAL INFORMATION</b>			
<b>3.2.R.1.1</b>	<b>Executed production document(s)</b> For applications accompanied by clinical data, the executed BMR should be for the batch(es) used in the clinical study			
<b>3.2.R.1.2</b>	<b>Master production documents</b>			
<b>Module 4</b>	<b>NON-CLINICAL DATA</b>			
	<i>Please refer to specific relevant SRA guidance where available for required non-clinical data e.g.,</i>  <b>erythropoietin:</b> EMA Guideline on non-clinical and clinical development of similar biological medicinal products containing recombinant erythropoietins			
<b>Module 5</b>	<b>CLINICAL DATA</b>			
	<i>Please refer to specific relevant SRA guidance where available for required clinical data e.g.,</i>			

	<p><b>soluble insulin:</b> EMA Guidance on similar medicinal products containing human soluble insulin</p> <p><b>erythropoietin:</b> EMA Guideline on non-clinical and clinical development of similar biological medicinal products containing recombinant erythropoietins</p>			
--	---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	--	--	--